HEPA
Hepion Pharmaceuticals, Inc.Company Information
- Company Name
- Hepion Pharmaceuticals, Inc.
- CIK
- CIK0001583771
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- HEPA: OTC, CTRVP: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- HEPA
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-08-03
- Last sale
- —
- Shares purchased (TTM)
- 26,500,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1
- Shares outstanding
- 16,193,404
- Ownership
- 0.00%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 25.71%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash | 2 | 3 | 2 | 2 | 3 | 5 | 0 | 1 | 2 | 13 | 15 | 19 | ||||||
| Prepaid Expense And Other Assets Current | - | - | - | - | - | - | - | - | 3 | 2 | - | 2 | ||||||
| Prepaid Expense Current | 0 | 0 | 1 | 1 | 2 | 2 | 1 | 1 | - | - | 3 | - | ||||||
| Assets Current | 2 | 3 | 3 | 4 | 5 | 6 | 2 | 4 | 5 | 15 | 17 | 21 | ||||||
| Assets | 2 | 3 | 3 | 4 | 5 | 6 | 2 | 4 | 6 | 16 | 18 | 25 | ||||||
| Indefinite Lived Intangible Assets Excluding Goodwill | - | - | - | - | - | - | - | - | - | - | 0 | 3 | ||||||
| Operating Lease Right Of Use Asset | - | - | 0 | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | - | - | - | - | - | - | - | 0 | - | - | 0 | - | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Property Plant And Equipment Net | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | ||||||
| Accrued Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 3 | ||||||
| Notes Payable Current | - | - | 0 | 0 | 0 | 1 | 3 | 2 | - | - | - | - | ||||||
| Other Liabilities Current | - | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Liabilities Current | 0 | 1 | 0 | 0 | 1 | 1 | 3 | 3 | 1 | 3 | 5 | 6 | ||||||
| Business Combination Contingent Consideration Liability Noncurrent | - | - | - | - | - | - | - | - | - | 1 | 2 | 2 | ||||||
| Operating Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Derivative Liabilities Noncurrent | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 5 | 4 | - | ||||||
| Deferred Income Tax Liabilities Net | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Liabilities | 1 | 1 | 0 | 0 | 1 | 2 | 3 | 4 | 2 | 8 | 11 | 9 | ||||||
Stockholders Equity | ||||||||||||||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | ||||||
| Business Combination Contingent Consideration Liability Current | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 248 | 247 | 247 | 247 | 247 | 246 | 234 | 234 | 233 | 233 | 230 | 228 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | 0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -248 | -247 | -246 | -245 | -245 | -244 | -238 | -236 | -231 | -227 | -225 | -214 | ||||||
| Stockholders Equity | 1 | 2 | 3 | 3 | 4 | 4 | -2 | 0 | 4 | 8 | 7 | 16 | ||||||
| Liabilities And Stockholders Equity | 2 | 3 | 3 | 4 | 5 | 6 | 2 | 4 | 6 | 16 | 18 | 25 | ||||||
| Series A Preferred Stock | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Series C Preferred Stock | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | 120 | ||||||
| Common Stock Shares Issued | 29 | 12 | 12 | 12 | 12 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Shares Outstanding | 29 | 12 | 12 | 12 | 12 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialHepion Pharmaceuticals, Inc. (HEPA) — SEC Financial Statements & Analysis
Hepion Pharmaceuticals, Inc. (HEPA) is a pharmaceutical preparations company, incorporated in DE. Hepion Pharmaceuticals, Inc. trades on OTC as: HEPA, CTRVP. Hepion Pharmaceuticals, Inc. (HEPA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Hepion Pharmaceuticals, Inc. carries a market cap of $1.10M, a P/E ratio of -0.35x, a P/B ratio of 0.86x, an enterprise value of $-527.47K, and an EV/EBITDA multiple of 0.17x. On profitability, it posts a Return on Equity (ROE) of -125.64%, a Return on Assets (ROA) of -99.13%, and a Return on Invested Capital (ROIC) of -546.49%. Per share, it reports EPS of $-0.20, diluted EPS of $-0.20, free cash flow per share of $-0.10, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -76.49% year-over-year and EPS growth of -83.55% year-over-year. On the balance sheet, it maintains a current ratio of 3.91x, a quick ratio of 3.31x, working capital of $1.43M, a debt-to-equity ratio of 0.51x, a debt ratio of 0.34, an interest coverage ratio of -108.29x, free cash flow of $-1.59M (TTM), and net debt of $-1.63M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.10M
- P/E TTM
- -0.35x
- EPS TTM
- $-0.20
- P/B TTM
- 0.86x
- ROE TTM
- -125.64%
- ROA TTM
- -99.13%
- Debt To Equity
- 0.51x
- Free Cash Flow TTM
- $-1.59M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Hepion Pharmaceuticals, Inc. in?
Hepion Pharmaceuticals, Inc. (HEPA) operates in the Pharmaceutical Preparations industry.
What exchange does HEPA trade on?
Hepion Pharmaceuticals, Inc. (HEPA) trades on the OTC.
Where is Hepion Pharmaceuticals, Inc. incorporated?
Hepion Pharmaceuticals, Inc. is incorporated in DE.
When was Hepion Pharmaceuticals, Inc. (HEPA)'s most recent SEC filing?
Hepion Pharmaceuticals, Inc. (HEPA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is HEPA's market cap?
Hepion Pharmaceuticals, Inc. (HEPA) has a market capitalization of $1.10M as of 2026-06-30.
What is HEPA's EPS (earnings per share)?
Hepion Pharmaceuticals, Inc. (HEPA)'s trailing twelve month EPS is $-0.20 as of 2026-06-30.
What is HEPA's ROE (return on equity)?
Hepion Pharmaceuticals, Inc. (HEPA)'s trailing twelve month Return on Equity (ROE) is -125.64% as of 2026-06-30.
What is HEPA's ROA (return on assets)?
Hepion Pharmaceuticals, Inc. (HEPA)'s trailing twelve month Return on Assets (ROA) is -99.13% as of 2026-06-30.
What is HEPA's ROIC (return on invested capital)?
Hepion Pharmaceuticals, Inc. (HEPA)'s trailing twelve month Return on Invested Capital (ROIC) is -546.49% as of 2025-12-31.
What is HEPA's EV/EBITDA?
Hepion Pharmaceuticals, Inc. (HEPA)'s trailing twelve month EV/EBITDA is 0.17x as of 2026-06-30.